Shanghai Runda Medical Technology Co., Ltd. (603108.SS)
CNY 17.64
(-1.07%)
CNY 17.64
(-1.07%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 6.85 Billion CNY | -0.2% |
| 2022 | 6.86 Billion CNY | 20.67% |
| 2021 | 5.68 Billion CNY | 26.62% |
| 2020 | 4.49 Billion CNY | 46.14% |
| 2019 | 3.07 Billion CNY | 26.91% |
| 2018 | 2.42 Billion CNY | -18.27% |
| 2017 | 2.96 Billion CNY | 129.31% |
| 2016 | 1.29 Billion CNY | 135.68% |
| 2015 | 548.37 Million CNY | 70.96% |
| 2014 | 320.75 Million CNY | 26.78% |
| 2013 | 253 Million CNY | 124.09% |
| 2012 | 112.9 Million CNY | 59.01% |
| 2011 | 71 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 6.67 Billion CNY | -15.33% |
| 2024 Q1 | 6.92 Billion CNY | 1.15% |
| 2024 Q2 | 7.01 Billion CNY | 1.31% |
| 2023 Q3 | 7.01 Billion CNY | -4.2% |
| 2023 Q2 | 7.32 Billion CNY | 1.6% |
| 2023 Q1 | 7.2 Billion CNY | 5.0% |
| 2023 FY | 6.85 Billion CNY | -0.2% |
| 2023 Q4 | 6.85 Billion CNY | -2.34% |
| 2022 Q4 | 6.86 Billion CNY | -0.48% |
| 2022 Q2 | 6.37 Billion CNY | 5.36% |
| 2022 FY | 6.86 Billion CNY | 20.67% |
| 2022 Q1 | 6.04 Billion CNY | 6.31% |
| 2022 Q3 | 6.89 Billion CNY | 8.26% |
| 2021 FY | 5.68 Billion CNY | 26.62% |
| 2021 Q1 | 4.94 Billion CNY | 10.14% |
| 2021 Q2 | 5.26 Billion CNY | 6.36% |
| 2021 Q3 | 5.9 Billion CNY | 12.12% |
| 2021 Q4 | 5.68 Billion CNY | -3.6% |
| 2020 Q4 | 4.49 Billion CNY | 0.24% |
| 2020 Q1 | 3.64 Billion CNY | 18.54% |
| 2020 Q2 | 4.65 Billion CNY | 27.83% |
| 2020 FY | 4.49 Billion CNY | 46.14% |
| 2020 Q3 | 4.48 Billion CNY | -3.78% |
| 2019 Q4 | 3.07 Billion CNY | 13.28% |
| 2019 Q2 | 2.75 Billion CNY | 1.43% |
| 2019 Q3 | 2.71 Billion CNY | -1.63% |
| 2019 FY | 3.07 Billion CNY | 26.91% |
| 2019 Q1 | 2.71 Billion CNY | 12.28% |
| 2018 Q2 | 2.95 Billion CNY | -3.63% |
| 2018 FY | 2.42 Billion CNY | -18.27% |
| 2018 Q4 | 2.42 Billion CNY | 0.8% |
| 2018 Q3 | 2.4 Billion CNY | -18.72% |
| 2018 Q1 | 3.06 Billion CNY | 3.51% |
| 2017 Q2 | 1.68 Billion CNY | 22.34% |
| 2017 FY | 2.96 Billion CNY | 129.31% |
| 2017 Q1 | 1.37 Billion CNY | 6.44% |
| 2017 Q4 | 2.96 Billion CNY | 15.68% |
| 2017 Q3 | 2.56 Billion CNY | 52.24% |
| 2016 Q1 | 607.81 Million CNY | 10.84% |
| 2016 Q4 | 1.29 Billion CNY | 17.05% |
| 2016 Q3 | 1.1 Billion CNY | 22.79% |
| 2016 Q2 | 899.23 Million CNY | 47.95% |
| 2016 FY | 1.29 Billion CNY | 135.68% |
| 2015 FY | 548.37 Million CNY | 70.96% |
| 2015 Q1 | 375.2 Million CNY | 16.98% |
| 2015 Q2 | 402.96 Million CNY | 7.4% |
| 2015 Q3 | 422.16 Million CNY | 4.76% |
| 2015 Q4 | 548.37 Million CNY | 29.9% |
| 2014 FY | 320.75 Million CNY | 26.78% |
| 2014 Q1 | - CNY | 0.0% |
| 2014 Q2 | 292.13 Million CNY | 0.0% |
| 2014 Q4 | 320.75 Million CNY | 0.0% |
| 2013 FY | 253 Million CNY | 124.09% |
| 2012 FY | 112.9 Million CNY | 59.01% |
| 2011 FY | 71 Million CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Joinn Laboratories(China)Co.,Ltd. | 85.79 Million CNY | -7884.897% |
| WuXi AppTec Co., Ltd. | 5.75 Billion CNY | -19.018% |
| Autobio Diagnostics Co., Ltd. | 1.03 Billion CNY | -559.852% |
| Thalys Medical Technology Group Inc. | 1.05 Billion CNY | -551.726% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 578.98 Million CNY | -1083.205% |
| Chemclin Diagnostics Co., Ltd. | 234.6 Million CNY | -2819.994% |